Table 3. Anti-B-CLL reactivity of... | American Society of Hematology

Table 3.

Anti-B-CLL reactivity of autologous anti-third-party CTLs

	B-CLL			B-CLL + autologous CTL
Patient no.	Mice per group, n	% CD 19/20⁺CD5⁺	Mice per group, n	% CD 19/20⁺CD5⁺	% B-CLL eradication^*
1	3	3.6	3	0.9	75†
2	4	5.7	1	3.35	42 (NS)
3	5	66.3	5	0.9	98.6‡
4	1	40.15	1	0.85	97.8 (NS)
5	7	14.4	6	6.1	57.6†
6	3	28.1	3	13.5	51.9†

	B-CLL			B-CLL + autologous CTL
Patient no.	Mice per group, n	% CD 19/20⁺CD5⁺	Mice per group, n	% CD 19/20⁺CD5⁺	% B-CLL eradication^*
1	3	3.6	3	0.9	75†
2	4	5.7	1	3.35	42 (NS)
3	5	66.3	5	0.9	98.6‡
4	1	40.15	1	0.85	97.8 (NS)
5	7	14.4	6	6.1	57.6†
6	3	28.1	3	13.5	51.9†

NS indicates not significant.

This value was calculated as follows: (% untreated - % treated/untreated) × 100.

Pf < .05.

Pf < 5 × 10⁻⁵.